Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma

Drug Design, Development and Therapy

Volumn 9, Issue , 2014, Pages 163-174

  Yeh, Chun Nan ^a   Hsieh, Feng Jen ^a   Chiang, Kun Chun ^a   Chen, Jen Shi ^b   Yeh, Ta Sen ^a   Jan, Yi Yin ^a   Chen, Miin Fu ^a  

^a Department of general surgery ^*  (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cholangiocarcinoma; Hepatectomy; Surgical margin

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL CHOLANGIOCARCINOMA; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL RATE; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HEPATECTOMY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84919676125     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74940     Document Type: Article

References (41)

1. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277–287.
2. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg. 2001;88: 969–974.
3. Chen MF, Jan YY, Wang CS, et al. Clinical experience in 20 hepatic resections for peripheral cholangiocarcinoma. Cancer. 1989;64: 2226–2232.
4. Vatanasapt V, Uttaravichien T, Mairiang EO, Pairojkul C, Chartbanchachai W, Haswell-Elkins M. Cholangiocarcinoma in north-east Thailand. Lancet. 1990;335:116–117.
5. Berdah SV, Delpero JR, Garcia S, Hardwigsen J, Le Treut YP. A western surgical experience of peripheral cholangiocarcinoma. Br J Surg. 1996;83:1517–1521.
6. Chu KM, Lai EC, Al-Hadeedi, et al. Intrahepatic cholangiocarcinoma. World J Surg. 1997;21:301–305.
7. Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB. 2008;10:164–167.
8. Todoroki T, Ohara K, Kawamoto T, et al. Benefts of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:581–587.
9. Gonzalez GD, Gouma DJ, Rauws EA, van Gulik TM, Bosma A, Koedooder C. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol. 1999;10:215–220.
10. Goldstein RM, Stone M, Tillery GW, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg. 1993;166:768–771.
11. Jeyarajah DR, Klintmalm GB. Is liver transplantation indicated for cholangiocarcinoma? J Hepatobiliary Pancreat Surg. 1998;5:48–51.
12. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarci-noma: results in 207 patients. Transplantation. 2000;69:1633–1637.
13. Yamamoto M, Takasaki K, Yoshikawa T, Ueno K, Nakano M. Does gross appearance indicate prognosis in intrahepatic cholangiocarci-noma? J Surg Oncol. 1998;69:162–167.
14. Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholan-giocellular carcinoma. Br J Surg. 2000;8:1182–1187.
15. Lang H, Sotiropoulos GC, Fruhauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005;241:134–143.
16. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors infu-encing survival. Br J Surg. 2002;89:1525–1531.
17. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg. 1999;6:122–127.
18. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Infuence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15: 2787–2794.
19. Jan YY, Ye h CN, Ye h TS, Hwang TL, Chen MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg. 2005;29:894–898.
20. Shirai K, Ebata T, Oda K, Nishio H, Nagino M. Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2008;32:2395–2402.
21. Shimada K, Sano T, Sakamoto Y, et al. Clinical impact of the surgical margin status in hepatectomy for solitary mass forming type intrahepatic cholangiocarcinoma without lymph node metastasis. J Surg Oncol. 2007;96:160–165.
22. Uenishi T, Hirohashi K, Kubo S, et al. Histological factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg. 2001;25:865–869.
23. Farges O, Fuks D, Boleslawsk E, et al. Infuence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma a mul-ticenter study by the AFC-IHCC-2009 Study Group. Ann Surg. 2011; 254:824–830.
24. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangio-carcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–3145.
25. Kawarada Y, Mizumoto R. Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepatogastroenterology. 1990;37:176–181.
26. Weinbren K, Mutum SS. Pathologic aspects of cholangiocarcinoma. J Pathol. 1983;139:217–238.
27. Ye h CN, Jan YY, Ye h TS, Hwang TL, Chen MF. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol. 2004;11:606–611.
28. Chen MF, Jan YY, Jeng LB, et al. Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg. 1999;6:136–141.
29. Yamashita Y, Taketomi A, Morita K, et al. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res. 2008;28:2353–2360.
30. Shirabe K, Mano Y, Taketomi A, et al. Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahe-patic cholangiocarcinoma: relevance of the lymphatic invasion index. Ann Surg Oncol. 2010;17:1816–1822.
31. Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schönleben F. Surgical treatment of mass forming intrahepatic cholangiocarcinoma: an 11-year Western single center experience in 107 patients. Ann Surg Oncol. 2009;16:404–412.
32. Inoue K, Makuuchi M, Takayama T, et al. Long term survival and prognostic factors in surgical treatment in mass forming type cholan-giocarcinoma. Surgery. 2000;127:498–505.
33. Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangio-carcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193:384–391.
34. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;8:242–451.
35. Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, Liau CT. Weekly 24 h infusion of high-dose 5-fuorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs. 1998;9: 393–397.
36. Chen JS, Lin YC, Jan YY, Liau CT. Mitomycin C with weekly 24-h infusion of high-dose 5-fuorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Drugs. 2001;12: 339–343.
37. Chen JS, Yang TS, Lin YC, Jan Y Y. A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J Clin Oncol. 2003;33:353–356.
38. Hsu C, Shen YC, Yang CH, et al. Weekly gemcitabine plus 24-h infusion of high-dose 5-fuorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer. 2004;90:1715–1719.
39. Chen JS, Chao Y, Yang TS, et al. A phase II trial of biweekly oxaliplatin with simplifed schedule of 48-h infusion of high-dose 5-fuorouracil and leucovorin for advanced biliary tract carcinoma. Cancer Chemother Pharmacol. 2009;65:151–157.
40. Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gem-citabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11: 1142–1148.
41. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–1940.